FDA PMTA Decisions Q3 2026: ZYN Ultra Authorized

TL;DR

The FDA's one nicotine pouch decision in Q3 2026 was a large one. On August 21, 2026, the agency authorized 11 ZYN Ultra products from Swedish Match, the first authorizations in the 9mg-and-above range. According to FDA's authorized-products list, that brings the total to 43 nicotine pouch products with marketing authorization, up from 32. VELO, Rogue, Lucy, and FRE continue operating with PMTAs pending review.

In one sentence: FDA's August 21 decision authorized ten ZYN Ultra flavors at 9mg and one at 11mg, lifting the authorized total to 43 while every non-ZYN, non-on! brand still waits.

Updated September 14, 2026 to reflect the August 21 authorization. An earlier version of this article described a Q3 authorization that did not occur.

The August 21 Authorization: ZYN Ultra

According to FDA's announcement "FDA Authorizes 11 New Nicotine Pouches," the agency issued marketing granted orders for 11 ZYN Ultra products on August 21, 2026. The products, as FDA lists them:

The asymmetry matters. Ten flavors are authorized at 9mg. Only one, Smooth, is authorized at 11mg.

According to FDA's announcement, the agency found these products "contain lower levels of most harmful and potentially harmful constituents" than other smokeless tobacco products when evaluated for their potential public health benefit. As with every prior authorization, this is a marketing determination under the Family Smoking Prevention and Tobacco Control Act, not a finding that the products are safe.

Retail names differ from FDA names

ZYN sells the Ultra line under different names than FDA uses on the authorization list. Per ZYN's own site, the eight retail varieties are Citrus Zest, Peppermint Frost, Wintergreen Blast, Arctic Mint, Fresh Spearmint, Menthol Ice, Chill Mist, and Signature Smooth. Neither FDA nor ZYN has published a mapping between the two sets of names, so this article does not assert one.

ZYN's site also states that every Ultra variety is sold in both 9mg and 11mg. Since FDA's list authorizes only Smooth at 11mg, some 11mg ZYN Ultra cans on shelves are not on the authorized list. Adults 21 and older who care about authorization status should check the strength on the can, not just the brand.

ZYN Ultra cans contain 20 pouches, per ZYN's site, compared with 15 in standard ZYN.

Current Landscape: 43 Authorized Products, Two Manufacturers

As of FDA's list current through August 21, 2026:

Swedish Match USA (ZYN): 31 products. The 20 standard ZYN SKUs authorized January 16, 2025 (10 flavors at 3mg and 6mg), plus the 11 ZYN Ultra products authorized August 21, 2026.

Helix Innovations (on!): 12 products. Six on! PLUS SKUs authorized December 19, 2025 (Mint, Tobacco, and Wintergreen at 6mg and 9mg), and six from the original on! line (Autumn Spice, Cappuccino, and Rich Berry at 2mg and 4mg).

Every other brand on the US market operates under the enforcement discretion policy described in FDA's premarket tobacco product application guidance. The full list is on our FDA-authorized nicotine pouches page and the PMTA tracker.

What This Means for Consumers 21 and Older

For adult users 21 and older, the Q3 2026 decision changes one thing materially: there are now FDA-authorized options above 6mg.

• Strength range widens: Authorized products now run from 2mg (on!) to 11mg (ZYN Ultra Smooth). Before August 21, the ceiling was on! PLUS 9mg.
• Still two manufacturers: Both authorized brands are owned by the two largest US tobacco companies. No independent brand has been authorized.
• Check the can, not the brand: The Ultra 11mg situation shows why. A brand being "FDA authorized" does not mean every SKU it sells is.
• No cessation claims: FDA authorization does not mean these products are approved for smoking cessation or any therapeutic use.

"FDA authorized" is distinct from "FDA approved." Authorization means FDA determined that marketing these specific products is appropriate for the protection of public health. The FDA's tobacco products overview states there is no safe tobacco product.

Industry Impact and Pending Applications

The slow pace of authorizations continues to create market uncertainty. Brands operating without authorization face potential marketing denial orders at any time.

Brands with PMTAs pending review (not authorized as of August 2026):

• VELO (R.J. Reynolds/BAT): PMTA submitted, no marketing authorization.
• Rogue (Swisher International): PMTA submitted, not authorized.
• Lucy (Lucy Goods Inc.): PMTA under FDA review.
• FRE (Turning Point Brands): PMTA submitted, no marketing authorization.

These brands submitted applications by the September 9, 2020 deadline and remain on the market while the FDA conducts reviews. Some applications have now been under review for nearly six years.

What's Next: Fall 2026 and Beyond

FDA has not published a review schedule. Based on the pattern so far, possible developments include:

1. More strength tiers for authorized brands: The Ultra authorization shows FDA will clear products above 6mg when the application supports it. Additional 11mg Ultra flavors are the obvious candidates.
2. First decisions on major pending brands: VELO, Rogue, Lucy, or FRE could receive first authorizations or denials.
3. Marketing denial orders: FDA could issue denials for products it determines are not appropriate for the protection of public health.

Updates appear on FDA's nicotine pouch page and in our PMTA tracker.

Regulatory Outlook

The August 21 decision is the largest single nicotine pouch authorization since the original 20 ZYN products in January 2025, and the first to clear anything above 9mg. It confirms that FDA is willing to authorize higher-strength oral nicotine products when the science supports it.

It also confirms the pattern. Forty-three authorized products, all from two manufacturers, both subsidiaries of the largest tobacco companies in the country. For every independent brand, the wait continues.

Adult consumers 21 and older should expect continued market evolution as the FDA works through the PMTA backlog.